RPCEC00000205已完成4 期
Security of CIMAvax-EGF® vaccine for the treatment of patients with NSCLC in advanced stages. Effectiveness exploration according to baseline concentrations of EGF. phase IV
Center of Molecular Immunology (CIM)0 个研究点开始时间: 2015年12月14日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 one（—）
- 性别
- All
入选标准
- •1. Patients of either sex and greater than or equal to 18 years.
- •2. Patients who met the diagnostic criteria.
- •3. Non-eligible patients for chemotherapy or radiotherapy or who have received the treatment oncospecific available and have no other treatment option.
- •4. Patients who have signed informed consent for research.
- •5. Patients with clinical criteria status (ECOG) 0 to 3.
- •6. Patients with a life expectancy greater than or equal to 3 months.
排除标准
- •1. Patients participating in another clinical trial.
- •2. Patients who have been treated with specific immunotherapy CIMAvax-EGF in the previous 6 months.
- •3. Patients who present a history of hypersensitivity to compounds similar to the vaccine or other component of the product formulation biological or chemical composition.
- •4. Patients of childbearing age who are not using an appropriate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). If male (vasectomy, condoms) during treatment
- •5. Patients who are pregnant, breastfeeding or postpartum.
- •6. Patients with brain metastases.
研究者
相似试验
已完成
4 期
CIMAVax EGF in Lung Cancer in PHC. Phase IVon-Small Cell advanced Lung CancerRPCEC00000181Center of Molecular Immunology (CIM)1,081
尚未招募
2 期
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM)Respiratory disorders in convalescent patients from SARS-CoV-2 infectionCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusLung DiseasesRespiratory Tract DiseasesPulmonary FibrosisRPCEC00000375Center of Molecular Immunology (CIM)135
已完成
不适用
CIMAvax-EGF in Bladder canceron-muscle invasive bladder cancerUrinary Bladder NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsCarcinoma in SituCarcinomaUrinary Bladder DiseasesUrologic DiseasesRPCEC00000331Center of Molecular Immunology (CIM)40
尚未招募
2 期
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutationsung CancerThoracic NeoplasmsRespiratory Tract NeoplasmsLung NeoplasmsCarcinoma, BronchogenicBronchial NeoplasmsCarcinoma, Non-Small-Cell LungLung DiseasesRespiratory Tract DiseasesRPCEC00000371Center of Molecular Immunology (CIM)20
尚未招募
1 期
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAXung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000370Center of Molecular Immunology (CIM)60